Money, explained for the rest of us.

Get our free daily email →

Medicare’s 2027 Ozempic price falls to $274 from $959

By

Image Credit: Chemist4U - CC BY-SA 2.0/Wiki Commons

Medicare’s second round of negotiated drug prices takes effect Jan. 1, 2027, and the biggest name on the list is the diabetes and weight-loss drug sold as Ozempic, Wegovy and Rybelsus. The Centers for Medicare & Medicaid Services (CMS) set its price at $274 for a 30-day supply, down from a $959 list price. Trelegy Ellipta, an inhaler for asthma and COPD, drops to $175 from $654.

All three semaglutide brands share the one price. They treat type 2 diabetes, cardiovascular disease and obesity or overweight, and the drug is one of 15 on the list. CMS says 5.3 million people in Medicare drug plans took the 15 drugs in 2024.

What the new price changes at the pharmacy

CMS estimates that people in Medicare prescription drug plans will save about $685 million in out-of-pocket costs in 2027 across all 15 drugs, according to its negotiated-price infographic. That is a program-wide total. CMS does not publish a copay for any single drug.

The $959 is the 2024 list price for a 30-day supply, the baseline CMS used for every drug on its list, so the $685 gap between the two numbers is the cut on paper, not a refund to a patient. Medicare drug plans pay pharmacies and manufacturers around these prices. A person’s own cost still depends on the plan’s deductible, coinsurance and any out-of-pocket limit.

That leaves a practical question for people who take Ozempic, Wegovy, Rybelsus, Trelegy or any of the other 12 drugs: what will their own plan charge in 2027? Medicare’s guide to 2027 changes says prices for the next 15 negotiated drugs take effect Jan. 1 and tells people to contact their plan for details on how those prices might affect them. Open Enrollment, the window for changing plans, runs Oct. 15 through Dec. 7.

The same guide advises people to review any changes to their costs and coverage before Open Enrollment and to compare their current coverage with 2027 options on Medicare.gov’s plan comparison tool. For someone on one of the 15 drugs, the comparison that matters is the plan’s 2027 cost for that exact prescription, not the national price CMS announced.

All 15 drugs and their negotiated prices

CMS’s fact sheet on 2027 prices compares each negotiated 30-day price with the drug’s 2024 list price for the same supply. The negotiated price is what CMS calls the MFP. The full list, from the deepest discount to the shallowest:

  • Janumet and Janumet XR (type 2 diabetes): $80, from $526, an 85% discount
  • Tradjenta (type 2 diabetes): $78, from $488, 84%
  • Breo Ellipta (asthma, COPD): $67, from $397, 83%
  • Linzess (constipation, irritable bowel): $136, from $539, 75%
  • Trelegy Ellipta (asthma, COPD): $175, from $654, 73%
  • Ozempic, Rybelsus and Wegovy: $274, from $959, 71%
  • Otezla and Otezla XR (psoriasis, psoriatic arthritis): $1,650, from $4,722, 65%
  • Xifaxan (liver and bowel conditions): $1,000, from $2,696, 63%
  • Pomalyst (multiple myeloma): $8,650, from $21,744, 60%
  • Ibrance (breast cancer): $7,871, from $15,741, 50%
  • Ofev (lung fibrosis): $6,350, from $12,622, 50%
  • Xtandi (prostate cancer): $7,004, from $13,480, 48%
  • Vraylar (bipolar disorder, depression, schizophrenia): $770, from $1,376, 44%
  • Calquence (blood cancers): $8,600, from $14,228, 40%
  • Austedo and Austedo XR (movement disorders): $4,093, from $6,623, 38%

Where the savings are biggest

The deepest cuts land on the diabetes and breathing drugs. Janumet, Tradjenta and Breo Ellipta all fall by more than 80%, and Linzess and Trelegy Ellipta by about three-quarters. The cancer drugs fall less in percentage terms, but the dollars are larger: Pomalyst drops by more than $13,000 a month on paper, and Ibrance and Xtandi by thousands.

In monthly terms, the gap between list and negotiated price is $685 for the semaglutide drugs, $479 for Trelegy Ellipta, $446 for Janumet, $410 for Tradjenta, $403 for Linzess, $330 for Breo Ellipta and $606 for Vraylar. Xifaxan falls by $1,696 and Otezla by $3,072. Those figures come from subtracting the two prices CMS prints in its fact sheet.

CMS says the 15 prices would have cut net Medicare spending on these drugs by about $12 billion, or 44%, if they had applied in 2024. The agency’s negotiation program page, last updated Nov. 2, 2026, still lists all 15 drugs with prices effective Jan. 1, 2027. It also lists four drugs that leave the program that day: Stelara, Entresto, Xarelto and Novolog/Fiasp.

Behind the price list sits a simple order of events. CMS ended its negotiation period on Nov. 1, 2025, published the prices later that month, and set Jan. 1, 2027 as the day they take effect. Nothing on the agency’s pages as of Nov. 2, 2026 moves that date.

These are the second set, not the first

Ten other drugs already carry negotiated prices that took effect Jan. 1, 2026, according to Medicare’s 2027 guide. Linzess, Xifaxan, Vraylar and Tradjenta are in the new group, so anyone who takes one of them sees the change in January. People on the 2026 drugs see no new price from this round.

Medicare’s guide also warns that using a discount card such as TrumpRx in place of Medicare coverage does not count toward the Medicare deductible or the out-of-pocket maximum. A person who pays cash for a semaglutide prescription instead of running it through the plan therefore gets no credit toward those limits.

This article was produced with AI assistance and edited for accuracy against the sources linked above.


Spotted an error? Tell us at [email protected]. We fix mistakes fast and in the open — see how we work on our standards page.